1. Show article details.

    Mylan to buy Swedish drugmaker Meda in $7.2 billion deal

    Reuters – 9:43 PM ET 02/10/2016

    - Generic drugmaker Mylan NV (MYL) said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company. The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo . Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer.

  2. Show article details.

    Abbott Introduces New 'Foodie' Inspired Snack Brand: Curate

    PR Newswire – 10:00 AM ET 02/09/2016

    ABBOTT PARK, Ill., Feb. 9, 2016  As snacks and smaller meals continue to be a big part of daily diets, people continue to look for snacks that are nutritious – made with wholesome, real food ingredients – but also have rich, complex flavors.

  3. Show article details.

    Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws

    PR Newswire – 9:11 AM ET 02/08/2016

    MERION, Pa., Feb. 8, 2016  The Law Offices of Marc S. Henzel, a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws: Cigna Corporation (CI)      2/27/14 thru 1/21/16.

  4. Show article details.

    Children in Europe Now Have Access to First-Of-Its-Kind Diabetes Sensing Technology - Eliminates Routine Finger Pricks(i)

    PR Newswire – 7:00 AM ET 02/04/2016

    ABBOTT PARK, Ill., Feb. 4, 2016 Today, Abbott announced that it has obtained CE Mark for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old.ii This means that children and young people with diabetes living in Europe are able to experience the liberation from the pain and hassle of routine finger pricks.i A person with diabetes ...

  5. Show article details.

    ALERE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alere Inc.

    PR Newswire – 1:31 PM ET 02/02/2016

    NEW ORLEANS, Feb. 2, 2016  Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Alere Inc. (ALR) to Abbott Laboratories.

  6. Show article details.

    Medical-Device Firms Use Deals To Branch Out

    DJ Business News – 2:47 AM ET 02/02/2016

    Medical-technology firms Abbott Laboratories (ABT) and Stryker Corp. (SYK) announced separate acquisitions with a combined value of $8.6 billion, aiming to further expand their portfolios beyond implanted devices and appeal to hospitals and clinics looking to bring down costs. Abbott agreed to pay $5.8 billion for diagnostic-testing company Alere Inc. (ALR), whose tests for HIV, malaria and the flu can deliver results faster than traditional laboratory tests that can take days to...

  7. Show article details.

    Abbott's Deal for Alere Tests Positive

    MarketWatch – 1:17 AM ET 02/02/2016

    Abbott Laboratories (ABT) announced Monday that it is buying AlereALR, which specializes in point-of-care diagnostic tests, for $5.8 billion, excluding net debt. Bringing Alere (ALR) into the fold allows the health-care giant to bulk up its own diagnostics business, which accounted for more than one-fifth of last year's revenue. The move comes as something of a surprise: Just last week, Abbott Chief Executive Miles Whiteindicated that health- care valuations are generally frothy.

  8. Show article details.

    Medical Tech Firms Branch Out

    DJ Business News – 5:45 PM ET 02/01/2016

    Medical technology firms Abbott Laboratories (ABT) and Stryker Corp. (SYK) announced separate acquisitions with a combined value of $8.6 billion, aiming to further expand their portfolios beyond implanted devices and appeal to hospitals and clinics looking to bring down costs. Abbott agreed to pay $5.8 billion for diagnostic-testing company Alere Inc. (ALR), whose tests for HIV, malaria and the flu can deliver results faster than traditional laboratory tests that can take days to process.

  9. Show article details.

    Medical Technology Firms Branch Out

    DJ Business News – 5:27 PM ET 02/01/2016

    Medical technology firms Abbott Laboratories (ABT) and Stryker Corp. (SYK) announced separate acquisitions with a combined value of $8.6 billion, aiming to further expand their portfolios beyond implanted devices and appeal to hospitals and clinics looking to bring down costs. Abbott agreed to pay $5.8 billion for diagnostic-testing company Alere Inc. (ALR), whose tests for HIV, malaria and the flu can deliver results faster than traditional laboratory tests that can take days to process.

  10. Show article details.

    Abbott Labs to Acquire Diagnostics-Testing Company Alere--Update

    DJ Business News – 9:59 AM ET 02/01/2016

    Abbott Laboratories (ABT) agreed to acquire diagnostic-test company Alere Inc. (ALR) for $5.8 billion, a deal Abbott expects will make it a leading provider of point-of-care testing. Alere (ALR) shares soared 45% to $53.84 in morning trading in New York, reflecting the deal price of $56 a share, a 51% premium to Friday's close. Abbott also said Alere's (ALR) net debt, currently about $2.6 billion, would be assumed or refinanced by Abbott.

  11. Show article details.

    Abbott Labs to buy Alere for $5.8 billion

    MarketWatch – 9:53 AM ET 02/01/2016

    Abbott says deal for diagnostics-testing company will expand its platforms to include benchtop and rapid-strip tests. Abbott Laboratories (ABT) agreed to acquire diagnostic-test company Alere Inc. (ALR) for $5.8 billion, a deal Abbott expects will make it a leading provider of point-of-care testing. Alere (ALR) shares soared 45% to $53.84 in morning trading in New York, reflecting the deal price of $56 a share, a 51% premium to Friday's close.

  12. Show article details.

    Abbott to Buy Alere for $5.8 Billion, Adding to Diagnostics Business

    DJ Business News – 9:15 AM ET 02/01/2016

    Abbott Laboratories (ABT) agreed to acquire diagnostic-test company Alere Inc. (ALR) for $5.8 billion, a deal Abbott expects will make it a leading provider of point-of-care testing. Alere (ALR) shares soared 45% to $53.84 in morning trading in New York, reflecting the deal price of $56 a share, a 51% premium to Friday's close. Abbott also said Alere's (ALR) net debt, currently about $2.6 billion, would be assumed or refinanced by Abbott.

  13. Show article details.

    Abbott Labs to Acquire Diagnostics-Testing Company Alere

    DJ Business News – 9:09 AM ET 02/01/2016

    Abbott Laboratories (ABT) agreed to acquire diagnostic-test company Alere Inc. (ALR) for roughly $4.8 billion, a deal Abbott expects will make it a leading provider of point-of-care testing. The company's news release Monday placed the equity value of the deal at $5.8 billion. An Abbott Laboratories (ABT) spokeswoman said the deal includes the impacts of restricted stock units, options and preferred shares.

  14. Show article details.

    Alere shares surge almost 50% on news of Abbott takeover

    MarketWatch – 8:15 AM ET 02/01/2016

    Alere Inc. (ALR) shares surged almost 50% in premarket trade Monday, after Abbott Laboratories (ABT) said it has agreed to buy the diagnostics company in a deal with an equity value of $5.8 billion. Abbott Labs (ABT) said it will pay $56 per Alere (ALR) share, or a 50% premium over Friday's closing price. "The combination of Alere (ALR) and Abbott will create the world's premier point of care testing business and significantly strengthen and grow Abbott's diagnostics presence," Abbott Chief Executive Miles...

  15. Alere shares up 48% in premarket trade

    MarketWatch – 8:05 AM ET 02/01/2016
  16. Abbott Labs expects deal to generate annual pretax synergies of about $500 mln by 2019

    MarketWatch – 8:04 AM ET 02/01/2016
  17. Abbott Labs expects deal to immediately boost earnings

    MarketWatch – 8:03 AM ET 02/01/2016
  18. Abbott Labs to pay $56 per Alere share

    MarketWatch – 8:02 AM ET 02/01/2016
  19. Abbott Labs agrees to buy Alere in $5.8 bln deal

    MarketWatch – 8:02 AM ET 02/01/2016
  20. Show article details.

    Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence

    PR Newswire – 8:00 AM ET 02/01/2016

    ABBOTT PARK, Ill. and WALTHAM, Mass. Abbott will be able to provide new, flexible, cost-effective, high-quality products to help health systems meet growing demand in both in-patient and out-patient settings.

Page:

Today's and Upcoming Events

  • Apr
    20

    ABT to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Jan
    28

    ABT Earnings Conference Call at 9:00 AM Listen

  • Jan
    13

    ABT ex-Dividend for $0.26 on 1/13/2016

    • Announce Date: 12/11/2015
    • Record Date: 1/15/2016
    • Pay Date: 2/16/2016
Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.